Medications for Treatment-Resistant Depression

Before another medication is added

The first question is not simply which drug comes next. It is whether the diagnosis, prior treatment, and current safety picture have been reviewed carefully enough to make the next decision useful.

A psychiatric reassessment may revisit bipolar symptoms, anxiety, trauma, substance use, sleep, thyroid or other medical conditions, pregnancy considerations, medication interactions, adherence, psychotherapy, and current suicidal or psychotic symptoms. It should also clarify whether earlier trials reached an appropriate dose and duration and what benefit or side effects actually occurred.

Optimize, switch, combine, or augment

These terms describe different strategies. Optimizing adjusts an existing plan; switching replaces a medication; combining uses more than one antidepressant; augmentation adds a treatment from another category.

There is no universal best medication or automatic order that fits every patient. The choice can depend on prior response, side effects, symptoms, medical conditions, other medications, urgency, patient preference, cost, and the monitoring a person can safely complete. Research comparing switch and add-on strategies does not support turning either one into a blanket rule.

Medication categories a psychiatrist may discuss

The conversation may include another antidepressant strategy, an adjunctive medication, a monitored lithium or thyroid strategy, a labeled combination, or supervised esketamine for an appropriate patient.

The exact product matters. Some adjunctive medications have FDA-labeled roles in major depressive disorder, while other strategies are off label. Lithium, thyroid hormone, antipsychotic-class medicines, and other add-on approaches have different evidence, interaction, laboratory, metabolic, or movement-monitoring considerations. SPRAVATO is an FDA-approved esketamine nasal spray delivered under a REMS-controlled pathway; ketamine used for depression follows a different, off-label pathway.

A webpage cannot identify the right drug or tell someone which medication to start. A prescriber should explain why a category fits, what benefit is being targeted, what risks matter, and what alternatives remain.

A monitoring plan belongs to the treatment

A medication decision is incomplete without a written plan for what will be measured, when it will be reviewed, and what safety changes require a call or urgent care.

• Name the target symptoms and daily functions the change is meant to improve.
• Set a follow-up timeline and define what would count as meaningful benefit.
• Review activation, mania symptoms, worsening suicidal thoughts, sedation, and other adverse effects.
• Match laboratory, blood-pressure, metabolic, movement, pregnancy, and interaction monitoring to the specific medication.
• Know who to contact, what happens if benefit is limited, and how any future taper or stop would be supervised.

When medication is not the whole next step

Medication changes may be one part of care, but the next conversation can also include psychotherapy, TMS, ECT, supervised esketamine, a higher level of care, or treatment of a condition affecting mood.

Severity and urgency matter. Psychosis, inability to care for basic needs, an immediate suicide plan, or danger to self or others can require emergency assessment or hospital-level care rather than another routine outpatient medication change.

Do not stop or change medication from a webpage

Stopping, skipping, combining, or changing a psychiatric medication without a clinician can cause withdrawal effects, interactions, symptom return, or other harm.

Use this page to prepare a focused conversation with the prescriber responsible for the plan. Bring a medication timeline, current medication and supplement list, side effects, benefit, and the questions you want answered.